Pre-made Itolizumab biosimilar ( Whole mAb, anti-CD6 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-284
Anti-CD6 therapeutic antibody (Pre-made Itolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD6 therapeutic antibody (Pre-made Itolizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium|
|Conditions Approved||Plaque psoriasis|
|Conditions Active||Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis|
|Conditions Discontinued||Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis|